Cracking Down On Silicone Implants

The controversy over silicone-filled breast implants has taken a new turn. On Aug. 22, the Food & Drug Administration notified three manufacturers that data they had submitted for safety reviews was insufficient. The three are Bioplasty, California doctor Joseph F. Cavon, and Bristol-Myers Squibb's Surgitek unit. The ruling could signal the end of their implants. Surgitek stopped marketing its implant in April after the FDA found that foam used in its manufacture could decompose into a carcinogenic material.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.